The Longevity Inflection Point
EpochRevive is positioned at the convergence of the most powerful scientific and economic wave of the 21st century. Here's why now.
Why Now
Validated Science
Nobel Prize-backed biology. Epigenetic clocks now provide objective, measurable endpoints.
$600B Market
The longevity economy is the fastest-growing segment of global biotech. This is not niche.
Inflection Point
Delivery technology has finally caught up with the underlying biology. The window is now.
Traction & Roadmap
Company Founded
Assembled founding team of 6 scientists and engineers.
Seed Round Closed
$4.2M seed from strategic research angels and family offices.
Preclinical Data
First in vivo data showing 31% epigenetic age reversal in aged mice.
Series A (In Progress)
Targeting $18M. Building out lab capacity and team.
IND Filing
Investigational New Drug application to FDA for age-related macular degeneration.
Phase I Trial
First-in-human clinical trial. Primary endpoint: biological age markers.
Ready to Learn More?
We're selective about our investor partners. We look for alignment on timeline, mission, and the willingness to back science that changes civilization.
Request Investor Briefing